DelveInsight’s Geography Atrophy pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Some of the Important Findings from the Geography Atrophy Market Report
There are currently 25+ drugs in the Geography Atrophy pipeline.
The Geography Atrophy pipeline consists of therapies in different clinical phase stages, including Pegcetacoplan, ALK-001, NGM621, RG6147, RO7303359, and others.
Leading players actively working to improve the Geography Atrophy treatment landscape are Apellis Pharmaceuticals, Alkeus Pharmaceuticals, NGM Biopharmaceuticals, Genentech, Roche, and others.
Key Geography Atrophy therapies in the late stage of development include Pegcetacoplan (Apellis Pharmaceuticals), ALK-001 (Alkeus Pharmaceuticals), and others.
RO7303359 is being developed and investigated in phase I Geography Atrophy clinical trials by Roche.
Get a detailed analysis of the pipeline landscape @ Geography Atrophy Pipeline Analysis
Geography Atrophy Overview
Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced Dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina (photoreceptors, retinal pigment epithelium, and choriocapillaris) over time, resulting in a loss of visual function.
Geography Atrophy Symptoms
The first Geography Atrophy symptom may be discovered while reading when one or more letters in a word are missing. When looking at faces, for example, a small portion of the face cannot be seen. Typically, once GA begins, the region of atrophy gradually expands over several years until central vision is lost and vision is around 20/200. Usually, it does not affect peripheral vision.
Geography Atrophy Treatment
Geographic Atrophy currently has no approved treatments. While there are no approved Geography Atrophy treatments, patients should be seen by an ophthalmologist regularly so that if they develop neovascular AMD, they can be treated. Patients can benefit from reading aids such as increased lighting, magnification, and low vision devices.
Geography Atrophy Pipeline Analysis: Drug Profiles
NGM621: NGM Biopharmaceuticals
Product Description
NGM621 is a humanised IgG1 monoclonal antibody designed to potently inhibit complement C3 activity, with the treatment goal of slowing disease progression in patients with geographic atrophy (GA) and the potential for every eight weeks dosing without pegylation.
Phase II
NCT04465955 (CATALINA): The Phase II CATALINA study, a multicenter, randomised, double-masked, sham-controlled clinical trial, is currently underway at NGM to assess the safety and efficacy of intravitreal injections (IVT) of NGM621 in patients with GA secondary to AMD.
Geography Atrophy Pipeline Therapies and Key Companies
Pegcetacoplan: Apellis Pharmaceuticals
ALK-001: Alkeus Pharmaceuticals
RG6147: Genentech
RO7303359: Roche
Find out the emerging therapies and companies @ Geography Atrophy Clinical Trails
Geography Atrophy Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Geography Atrophy Key Players: Apellis Pharmaceuticals, Alkeus Pharmaceuticals, NGM Biopharmaceuticals, Genentech, Roche, among others
Geography Atrophy Pipeline Therapies: Pegcetacoplan, ALK-001, NGM621, RG6147, RO7303359, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Geographic Atrophy: Overview
4.
Geographic Atrophy- Analytical Perspective In-depth Commercial Assessment
5.
Geographic Atrophy Pipeline Therapeutics
6.
Geographic Atrophy Late Stage Products (Phase III)
7.
Geographic Atrophy Mid Stage Products (Phase II)
8.
9.
Geographic Atrophy Early Stage Products (Phase I)
10.
Geographic Atrophy Therapeutic Assessment
11.
Geographic Atrophy Inactive Products
12.
Geographic Atrophy Company-University Collaborations (Licensing/Partnering) Analysis
13.
Geographic Atrophy Key Companies
14.
Geographic Atrophy Key Products
15.
Geographic Atrophy- Unmet Needs
16.
Geographic Atrophy- Market Drivers and Barriers
17.
Geographic Atrophy- Future Perspectives and Conclusion
18.
Geographic Atrophy Analyst Views
19.
Appendix
20.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Geography Atrophy Pipeline Report
What Geography Atrophy treatments are available?
How many pharmaceutical companies are working on treatments for Geography Atrophy?
Which of these companies’ pharmaceuticals is the most commonly used?
How many Geography Atrophy medications are manufactured by each company?
How many drugs targeting Geography Atrophy are in early, mid, or late development?
How many of the therapies that are currently being developed can be used alone or in combination with other treatments?
What are the most important collaborations, mergers and acquisitions, and licencing practises in Geography Atrophy?
Related Reports
Age-Related Macular Degeneration Pipeline Insights
“Age Related Macular Degeneration Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Age-Related Macular Degeneration market.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/